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ORIGINAL ARTICLE MYCOLOGYEarly initiation of appropriate treatment is associated with increased
survival in cancer patients with Candida glabrata fungaemia: a potential
beneﬁt from infectious disease consultationDimitrios Farmakiotis1,2,4, A. Kyvernitakis1, J. J. Tarrand3 and D. P. Kontoyiannis1
1) Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 2) Infectious Disease Section,
Baylor College of Medicine , 3) Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA and 4) Division of Infectious
Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MAAbstractIn patients with malignancies, Candida glabrata is one of the most frequent non-albicans Candida clinical isolates. As antifungal resistance in
C. glabrata is common, we investigated the relationship between early appropriate antifungal treatment, infectious disease (ID) consultation
and mortality in a contemporary cohort of cancer patients with C. glabrata fungaemia. We included patients with at least one C. glabrata-
positive blood culture and symptoms or signs of infection seen at the MD Anderson Cancer Center between March 2005 and September
2013. In vitro susceptibility to antifungals was deﬁned according to the 2010 CLSI clinical breakpoints. One-hundred and forty-six episodes of
candidaemia were studied. Thirty isolates (20.5%) had ﬂuconazole MIC  64 mg/L and 15 (10.3%) were caspofungin-resistant. Early (within
48 h after blood culture collection) initiation of appropriate antifungal treatment (hazard ratio 0.374, p 0.003) and early ID consultation
(hazard ratio 0.421, p 0.004) were associated with decreased mortality, after adjustment for signiﬁcant confounders. Thirty-two of 58
patients (55.2%) followed by ID were on appropriate antifungals within 48 h, compared with 16/88 patients (18.2%) who were not followed
by ID an ID specialist (p <0.001). The median time-to-reporting of blood culture positivity for yeast was 71 h. Delayed time-to-reporting was
associated with increased 28-day all-cause mortality (log-rank p 0.023). The beneﬁts from early initiation of appropriate antifungal treatment
and ID consultation were more prominent in patients with non-catheter-related candidaemia. In conclusion, in cancer patients with
C. glabrata fungaemia, early ID consultation may lead to timely initiation of appropriate treatment and improved clinical outcomes.
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setting of prophylaxis and pre-emptive or empiric treatmentClinical Microbiology and Infection © 2014 European Society of Cprotocols has led to a notable shift from albicans to non-albicans
Candida species [1–4].Candida glabrata is among themost frequent
species isolated from patients with malignancies, and the main
species exhibiting multiazole, echinocandin and multidrug resis-
tance (MDR; resistance to at least two classes of antifungals) [5,6].
Previous studies of candidaemia showed that early adminis-
tration of ﬂuconazole improved survival rates [7,8]. Adherence
to national guidelines and infectious disease (ID) consultation led
to a signiﬁcant decrease in mortality rates [9,10]. Nevertheless,
the relationship between early appropriate antifungal treatment
and clinical success is not clear in the current era of high
prevalence of resistance, especially in immunocompromisedClin Microbiol Infect 2015; 21: 79–86
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2014.07.006
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early initiation of appropriate treatment [11–14], whereas
others did not [15–18].
As cancer patients with C. glabrata bloodstream infections
often have multiple risk factors for treatment failure and
adverse outcomes [2,4,5,19], it is important to identify in-
terventions associated with increased survival, independent of
host factors and source control. Therefore, we sought to
investigate the correlation of clinical outcomes with early
initiation of appropriate treatment and ID consultation, in a
contemporary cohort of cancer patients with C. glabrata
fungaemia.Patients and methodsData collection
We included patients with at least one blood culture(s) posi-
tive for C. glabrata, in addition to symptoms, signs (fever, hy-
pothermia, tachycardia, hypotension or altered mental status)
and/or laboratory ﬁndings (leucocytosis or leucopenia,
thrombocytopenia or acidosis) consistent with infection, seen
at MD Anderson Cancer Center between March 2005 and
September 2013. We retrospectively reviewed electronic
medical records for clinical and laboratory data on the day of
blood culture collection, treatment, ID consultation, 28-day
mortality and in-hospital all-cause mortality. Speciation of
C. glabrata and antifungal susceptibility testing were performed
as previously described (see Supporting information)
[2–4,20,21]. The study was approved by the Institutional Re-
view Board.
Deﬁnitions
Catheter-related candidaemia was deﬁned as a patient with a
colony count in a blood culture obtained via a central venous
catheter (CVC) at least ﬁvefold greater than the colony count
in a peripheral blood culture, or a case with positive catheter
tip culture [2,22].
Appropriate treatment was deﬁned as amphotericin B for
susceptible isolates, an echinocandin for isolates with caspo-
fungin MIC <0.5 mg/L, or 800 mg of ﬂuconazole daily for iso-
lates with ﬂuconazole MIC <64 mg/L (dose-dependent)
[1,11,23]. Given the suboptimal responses of serious C. glabrata
infections to azoles and the lack of clinical breakpoints for
voriconazole, voriconazole was considered appropriate treat-
ment only for ﬂuconazole dose-dependent isolates with
MIC <1 mg/L (one dilution above the epidemiological break-
point) [21,23]. ID consultation within 48 h after blood culture
collection referred to both the initial consultation and patients
who were already followed by ID an ID specialist.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectStatistical analysis
Normality of distribution was tested with the Kolmogorov–
Smirnoff test. Continuous variables were compared with Student’s
t-test or the Mann–Whitney U-criterion for variables that were
not normally distributed. Categorical variables were compared
using the chi-square or Fisher exact test (expected frequency <5).
We identiﬁed early interventions as those that occurred within
48 h after blood culture collection, and repeated all survival ana-
lyses after excluding patients who died within that time period.
Time-to-event survival analyses have beenwidely implemented
in studies of candidaemia [11,24] as they allow more power to
unmask potential physiological beneﬁts [25], given the complex
patient populations and frequent small sample sizes. However, in
the critically ill, it has been argued that logistic regression using a
dichotomous outcome is more appropriate, because for patients
who die in the hospital, a prolonged stay does not reﬂect actual
beneﬁt [25]. Therefore, we addressed two outcome measures: a)
28-day survival analysed by the log-rank test and Cox regression,
and b) all-cause in-hospital mortality rates, compared by binary
logistic regression. The proportional hazards assumption was
tested graphically and by building time-dependent variables. Nu-
merical parameters were tested in different models both as scale
and dichotomous variables (greater than versus less than the
mean and/or widely used cut-off values of clinical signiﬁcance).
Clinically relevant parameters (univariate p <0.2) were included at
model entry. Appropriate treatment and ID consultation were
forced separately in all multivariate analyses. Variables were
retained in the ﬁnal model if the p value was <0.05.
All analyses were performed with SPSS statistical software,
version 21, IBM Corporation (Armonk, NY, USA). Two-tailed p
values <0.05 were considered statistically signiﬁcant. Values of p
>0.05 but <0.1 were noted as indicating trends.ResultsPatient population and in vitro susceptibilities
We identiﬁed 146 episodes of C. glabrata fungaemia. The de-
mographic, clinical and laboratory characteristics of all patients
are listed in Table 1. Thirty isolates (21%) had ﬂuconazole
MIC 64 mg/L. Twenty-four isolates (16%) were intermediate
and 15 (10.3%) were resistant to caspofungin. Ten of 15
caspofungin-resistant isolates (67%) met the deﬁnition for MDR
[6]: nine had ﬂuconazole MIC 64 mg/L and one was resistant
to amphotericin B. Antifungal MIC distributions are summa-
rized in the Supporting information, Fig. S1.
Factors associated with all-cause mortality
The 28-day all-cause mortality rate was 40% (58/146), and the
in-hospital mortality rate was 46.6% (68/146). Factorsious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 79–86
TABLE 1. Basic demographic, clinical and laboratory
characteristics of the 146 patients studied on the day of the
positive for Candida glabrata blood culture collectiona
Characteristic n (%)
Host
Age (years, mean (SD), range) 55.02 (14.99), 12–85
Male sex 75 (51)
Solid tumourb 99 (68)
Haematological malignancy 47 (32)
AML 17 (12)
ALL 5 (3)
Lymphoma 15 (10)
Multiple myeloma 4 (3)
Myelodysplastic syndrome 2 (1)
Other 4 (3)
HSCT 16 (11)
Diabetes mellitus 23 (16)
Chronic kidney disease 24 (16)
Chronic liver disease 18 (12)
Recent abdominal surgery (within 1 month) 26 (18)
TPN 36 (25)
Clinical disease
Fever (>38 °C) 63 (43)
Mixed bloodstream infection 28 (19)
ICU stay 59 (40)
Mechanical ventilation 27 (19)
Septic shock (administration of vasopressor) 34 (23)
APACHE II score, mean (SD) 14.58 (6.97)
APACHE II score 20 38 (26)
Presence of a central line 131 (90)
Catheter-related candidaemia 60 (41)
Recent (within 1 month) drug exposures
Chemotherapy 69 (47)
Corticosteroids 85 (58)
Antibacterials 144 (99)
Azoles 44 (30)
Echinocandins 32 (22)
Laboratory ﬁndings
Neutropenia (AMC < 500/μL) 28 (19)
AMC 100–500/μL 9 (6)
AMC < 100/μL 19 (13)
Lymphopenia (ALC < 500/μL) 86 (59)
Monocytopenia (AMC < 100/μL) 39 (27)
AKI or ARFc 48 (33)
Acute liver injuryd 23 (16)
Abbreviations: AKI, acute kidney injury; ALC, absolute lymphocyte count; ALL,
acute lymphoblastic leukaemia; AMC, absolute monocyte count; AML, acute
myeloid leukaemia; APACHE, acute physiology and chronic health evaluation score;
ARF, acute renal failure; HSCT, haematopoietic stem cell transplantation; ICU,
intensive care unit; TPN, total parenteral nutrition.
aData are presented as absolute numbers (%) unless otherwise indicated for nor-
mally distributed variables or median numbers (25th-75th percentile) for variables
that were not normally distributed.
bForty-seven (32%) gastrointestinal tumours, 12 (8%) gynaecological tumours, 9
(6%) genitourinary tumours, 6 (4%) breast tumours, 6 (4%) lung tumours, 4 (3%)
thyroid tumours, 4 (3%) sarcomas, 3 (2%) head and neck tumours, 2 (1%) central
nervous system tumours, and 6 (4%) other tumours.
cDecrease in estimated glomerular ﬁltration rate by 50% or 100% from baseline,
respectively, or initiation of renal replacement treatment.
dThreefold increase in alanine aminotransferase level from baseline.
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Table 2. There was no association with age, sex or type of
malignancy. Acute Physiology and Chronic Health Evaluation
(APACHE) II score, recent corticosteroid administration,
mixed bacterial bloodstream infections, non-catheter-related
candidaemia, lack of early appropriate antifungal treatment
and absence of early ID consultation were independently
associated with increased 28-day mortality. Exclusion of pa-
tients who died within 48 h after blood culture collection or
entering the APACHE II score as a categorical variable (15
vs.<15 or <20), did not affect the signiﬁcance of independent
associations between 28-day mortality and other parameters.Clinical Microbiology and Infection © 2014 European Society of Clinical MicrobioloThe mean time-to-reporting of culture positivity for yeast
(available for 129 patients) was 75 h (SD 33.76, median 71 h,
25th–75th percentile: 21–96 h). Delayed time-to-reporting
(> 72 h) was associated with increased 28-day all-cause mor-
tality (log-rank p 0.023).
Early appropriate antifungal treatment
Patients who received early appropriate antifungal treatment
were more likely to be in the intensive care unit (52.1% versus
34.7%, p 0.044) and in septic shock (33.3% versus 18.4%,
p 0.044), compared with those who did not. Early appropriate
antifungal treatment was independently associated with
decreased 28-day mortality (Table 2) and in-hospital mortality
(adjusted odds ratio 0.31, p 0.011; see Supporting information,
Table S1). The antifungal agents administered during the ﬁrst
48 h and at any time before hospital discharge or death are
summarized in Table 3. Among the 48 patients who received
early appropriate antifungal treatment, appropriate therapy
constituted starting an antifungal agent in 30 patients (62.5%)
and modifying existing antifungals in eight patients (16.7%). Ten
patients (20.8%) were already receiving appropriate antifungal
treatment at the time of positive blood culture.
ID consultation
Patients who underwent early ID consultation were more likely
to have received haematopoietic stem cell transplantation (19%
versus 5.7%, p 0.012), be in septic shock (32.8% versus 17%,
p 0.028), and have ﬂuconazole-resistant isolates (29.3 versus
14.8%, p 0.033), compared with those who did not. In multi-
variate analysis, we observed a strong contribution of early ID
consultation to 28-day survival, after controlling for other
confounders (adjusted hazard ratio, 0.421; p 0.004, Table 2).
We also noted a trend for independent association between
early ID consultation and in-hospital mortality (adjusted odds
ratio 0.462, p 0.063; see Supporting information, Table S1).
Thirty-two of 58 patients (55%) who had early ID consul-
tation (57%; 32 of the 56 who survived more than 48 h)
received appropriate antifungals within 48 h after blood culture
collection, as opposed to 16 of 88 patients (18%) who did not
undergo early ID consultation (17.5%; 14 of the 80 patients
who survived more than 48 h; p <0.001). Therefore, the effects
of early appropriate antifungal treatment and ID consultation
were less signiﬁcant when both parameters were included in
multivariate analysis than with inclusion of either of them alone
(Table 2; see Supporting information, Table S2).
Among the 26 patients with early ID consultation who were
not started on early appropriate antifungal treatment, two pa-
tients received an echinocandin plus an azole for MDR isolates.
Four additional patients were treated with echinocandins for
caspofungin-resistant isolates; seven patients receivedgy and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 79–86
TABLE 2. Factors associated with 28-day all-cause mortality in cancer patients with Candida glabrata fungaemia
Factor
Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
ICU stay 2.169 1.291–3.643 0.003
HSCT 1.77 0.869–3.607 0.116
Neutropenia 1.525 0.835–2.784 0.170
Monocytopenia 1.485 1.141–1.934 0.003
APACHE II score 1.107 1.066–1.150 <0.001 1.084 1.041–1.129 <0.001
Mechanical ventilation 2.712 1.549–4.750 <0.001 2.156 1.124–4.138 0.021
Septic shock 2.735 1.604–4.663 <0.001
AKI or ARF 1.884 1.120–3.171 0.017
Fever 0.517 0.299–0.896 0.019
Corticosteroidsa 2.961 1.596–5.494 0.001 2.919 1.550–5.499 0.001
Catheter-related candidaemia 0.451 0.253–0.802 0.007 0.496 0.268–0.919 0.026
Mixed bloodstream infection 1.906 1.058–3.436 0.032 2.961 1.580–5.550 0.001
Fluconazole resistance (64 mg/L) 1.727 0.971–3.074 0.063
Caspofungin resistance (0.5 mg/L) 2.117 1.036–4.324 0.04
Echinocandin pre-exposurea 2.075 1.197–3.598 0.009
CVC removal within 48 h after blood culture collectionb 0.356 0.157–0.998 0.049
ID consultation within 48 h after blood culture collectionc 0.678 0.392–1.174 0.166 0.537 0.290–0.996 0.048c
Appropriate treatment within 48 h after blood culture collectiond 0.463 0.245–0.874 0.018 0.469 0.237–0.930 0.030d
Abbreviations: AKI, acute kidney injury; ARF, acute renal failure; CVC, central venous catheter; HR, hazard ratio; HSCT, haematopoietic stem cell transplantation; ICU, intensive
care unit; ID, infectious disease.
aWithin 1 month before blood culture collection.
bAmong patients with a central venous catheter in place.
cHR 0.421, 95% CI 0.233–0.760 (p 0.004) after removal of appropriate treatment within 48 h after blood culture collection from the model and HR 0.418, 95% CI 0.220–0.796 (p
0.008) after exclusion of patients who died within 48 h after blood culture collection.
dHR 0.374, 95% CI 0.197–0.709 (p 0.003) after removal of ID consultation from the model and HR 0.357, 95% CI 0.178–0.718 (p 0.004) after exclusion of patients who died within
48 h after blood culture collection.
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zole MIC 64 mg/L). Thirteen patients (50%) did not receive
any early antifungal treatment. Ten of those patients were
started on appropriate treatment after blood cultures were
reported as positive. The remaining three patients died before
their blood cultures were reported as positive. Therefore,
delayed diagnosis (13/26, 50%) and resistance (8/26, 30.7%)
were the main reasons for lack of early appropriate antifungal
treatment in patients who underwent early ID consultation.
Catheter-related versus non-catheter-related
C. glabrata fungaemia
Sixty patients had catheter-related candidaemia based on paired
quantitative blood cultures. Two of those also had a positive
catheter tip culture. The positive associations of early initiationTABLE 3. Antifungal treatment in 146 cancer patients with
Candida glabrata fungaemia, n (%)
Initial treatmenta Any treatmentb
No treatment 56 (38.4) 24 (16.4)
Azole monotherapy 34 (23.3) 23 (15.8)
Echinocandin monotherapy 38 (26) 62 (42.5)
AMB monotherapy 4 (2.7) 4 (2.7)
Multiple antifungals
Azole + echinocandin 9 (6.2) 16 (11)
Azole + AMB — 2 (1.4)
Echinocandin + AMB 4 (2.7) 7 (4.8)
Azole + echinocandin + AMB 1 (0.7) 8 (5.5)
Abbreviation: AMB, Amphotericin-B.
aAntifungal treatment administered within 48 h after blood culture collection.
bAny antifungal treatment administered from the date of candidaemia until death or
discharge from the hospital.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectof appropriate treatment and early ID consultation with 28-day
survival and discharge from the hospital were observed pre-
dominantly in patients with non-catheter-related candidaemia
(Fig. 1; see Supporting information, Tables S2 and S3).
In all patients with a CVC, and in those with catheter-related
candidaemia, catheter removal within 48 h after blood culture
collection was associated with decreased all-cause mortality in
univariate, but not multivariate, analysis. We did not ﬁnd an
association between mortality and early CVC removal in pa-
tients with CVC and non-catheter-related candidaemia
(Table 2, Fig. 1).DiscussionIn the present series of cancer patients with C. glabrata fungaemia,
early initiation of appropriate treatment and ID consultation
were associated with decreased all-cause mortality, after
adjustment for other confounders. This effect was more prom-
inent in immunocompromised and critically ill patients with non-
catheter-related candidaemia, such as those with prolonged
neutropenia or complicated intra-abdominal pathology.
Appropriate antifungal treatment given within 48 h after
blood culture collection was independently associated with
decreased 28-day and in-hospital mortality, which is in agree-
ment with some [2,11–14], but not all [15–18], previous re-
ports. In all of those previous studies, a signiﬁcant proportion of
fungaemia episodes were caused by Candida albicans. Timelyious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 79–86
FIG. 1. Comparison of Kaplan–Meier curves by the log-rank test in cancer patients with catheter-related candidaemia (left) or candidaemia from
other sources (right), showing the association of early (within 48 h after blood culture collection) interventions (AAT, ID and CVC removal) with 28-
day all-cause mortality. Abbreviations: AAT, appropriate antifungal treatment; ID, infectious disease consultation; CVC, central venous catheter.
CMI Farmakiotis et al. C. glabrata fungaemia in cancer patients 83initiation of appropriate treatment is particularly important for
infections with C. glabrata, a species that is virulent and often
resistant to antifungals [5], but is associated with slower in vitro
growth, which can delay the initiation of treatment [11,13]Clinical Microbiology and Infection © 2014 European Society of Clinical MicrobioloThe correlation between time-to-positivity and outcome is
of particular interest. In a previous study of candidaemia,
delayed culture positivity was associated with decreased all-
cause mortality, in contrast to our results [11]. However, thegy and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 79–86
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tropicalis, both of which exhibit faster in vitro growth [11,13],
compared with C. glabrata. In our study, the median time-to-
reporting of C. glabrata-positive blood cultures was almost 3
days, and longer times-to-reporting correlated with increased
mortality. Our results underscore the importance of a high
clinical suspicion and timely administration of effective treat-
ment in C. glabrata fungaemia, before blood cultures are re-
ported as positive. Indeed, the high mortality associated with
candidaemia in the present and previous [7,8,14] reports can be
attributed to the long time that is needed for culture-based
diagnosis [26]. Speciﬁcally, in a recent study of candidaemic
patients in septic shock [14], the median time-to-positivity
across different Candida species was more than 2 days (55 h),
but administration of appropriate antifungals within 24 h after
blood culture collection was independently associated with
increased survival rates, in agreement with our ﬁndings.
Furthermore, in our study, delayed culture-based diagnosis was
the main reason for not initiating appropriate antifungals within
48 h after blood sample collection, among patients who were
followed by ID specialists. It should be noted that new tech-
nologies, such as β-D-glucan and PCR-based assays, can assist in
the early diagnosis of candidaemia and guide the initiation of
empirical treatment, leading to better clinical outcomes [26].
In our study, threefold more patients who had an ID
consultation than those who did not received adequate treat-
ment for candidaemia within 48 h after blood culture collection.
Early ID consultation was associated with decreased all-cause
mortality after controlling for host characteristics and disease
severity, especially in patients with non-catheter-related can-
didaemia. Our ﬁndings are in agreement with those in two
previous reports [9,10]. Nevertheless, factoring local epidemi-
ology regarding species distribution and resistance into thera-
peutic decision-making is paramount in the care of patients with
candidaemia and, to our knowledge, no previous studies
focused on the role of early ID consultation input for candi-
daemia in the current era of high non-albicans Candida spp.
prevalence and antifungal resistance. In one of the studies
described above, the researchers did not report susceptibility
or timing of ID consultation [9]. In the other, most of the
isolates were susceptible to ﬂuconazole [10]. In cancer patients
with candidaemia, ID consultation can contribute to optimiza-
tion of care through not only prompt initiation of appropriate
antifungals and source control, but also management of other
concomitant infections, medication toxicity and antifungal
stewardship [27]. The latter is of particular importance in the
cancer patient population, because our rates of in vitro caspo-
fungin and MDR were among the highest reported to date.
Similar to previous studies [12,22], early CVC removal was
associated with increased survival only in the subgroup ofClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectpatients with catheter-related fungaemia, whereas timely initi-
ation of appropriate treatment was associated with decreased
mortality in those with non-catheter-related infections. The
beneﬁt of early catheter removal decreased after adjustment
for other confounders, which was similar to a previous study
[28], but contrasted with the results of other investigators
[12,24,29]. It should be noted that the absence of an indepen-
dent association in our study may have resulted from the small
number of patients who underwent early CVC removal.
Although removal of a catheter is considered the standard of
care in the treatment of candidaemia [1], larger prospective
studies are still needed to better identify the independent as-
sociation between early CVC removal and outcomes in
catheter-associated C. glabrata fungaemia.
Our retrospective, single-centre study had several limita-
tions. First, our observations might not be applicable to
different patient groups at risk for candidaemia, or different
Candida species. Second, using caspofungin MIC without data
regarding FKS mutations might have led to overestimation of
echinocandin resistance [5]. Third, a signiﬁcant proportion of
patients (38%, Table 3) did not receive any antifungal treatment
within 48 h, and in the majority of those who did (63%), anti-
fungal therapy was initiated, not changed. Therefore, our study
was not powered to detect differences regarding early admin-
istration of speciﬁc antifungals, modiﬁcation of treatment, or
combination regimens. Finally, our outcome measure was all-
cause mortality, and we did not report any data on Candida-
attributable mortality or mycological response. However, the
autopsy rate at our institution is low [30], and sterilization of
blood cultures does not always reﬂect the success and effective
timing of interventions, especially after initiation of the sepsis
cascade in immunocompromised patients. By assessing all-cause
mortality, an objective outcome measure widely used in
retrospective studies of candidaemia [11,14,15–20,24], we
believe that we captured an important beneﬁt from timely
appropriate treatment and ID consultation.
In conclusion, in cancer patients with C. glabrata fungaemia,
having high rates of antifungal resistance, early initiation of
appropriate treatment and ID consultation were associated
with increased survival. Candidaemia is another indication
where early involvement of an ID specialist may lead to timely
initiation of adequate treatment and improved outcomes, along
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